Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
FDA Approves Test to Identify Gastroesophageal Cancer Patients Eligible for Jazz Pharmaceuticals' Ziihera

FDA Approves Test to Identify Gastroesophageal Cancer Patients Eligible for Jazz Pharmaceuticals' Ziihera

MT newswireMT newswire2026/08/26 19:52
03:52 PM EDT, 08/26/2026 (MT Newswires) -- The US Food and Drug Administration has approved usage of Roche's diagnostics tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma patients who may be eligible for treatment with Jazz Pharmaceuticals' (JAZZ) Ziihera, Roche said Wednesday. Roche further said that two Ziihera-containing regimens are now FDA approved for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive GEA. Shares of Jazz Pharmaceuticals were down 4.3% in Wednesday trading. Price: 250.04, Change: -10.19, Percent Change: -3.92
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Goldman Sachs remains bullish on the South Korean stock market: Driven by the AI memory boom, with a potential upside of up to 80%.

Goldman Sachs strategist Timothy Moe maintains his bullish target on the South Korean stock market, believing that investors are underestimating how long the benefits of artificial intelligence (AI) will last for the country's memory chip manufacturers.

智通财经2026/09/07 01:51
Goldman Sachs remains bullish on the South Korean stock market: Driven by the AI memory boom, with a potential upside of up to 80%.